Keyword: Fractyl Laboratories
Fractyl presented new data from two trials of its intestine-resurfacing procedure, including demonstrated improvements in Type 2 diabetes.
Early clinical data from Fractyl showed its outpatient procedure could help eliminate several months’ worth of insulin injections.
Fractyl plans to use the funds to develop its water-filled balloon device, Revita DMR.
Fractyl Labs reported data from the first-in-human study of its endoscopic duodenal mucosal resurfacing treatment.